Evaluating the safety and effectiveness of Sotyktu for plaque psoriasis in Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and effectiveness of deucravacitinib, also known as Sotyktu, in adult patients diagnosed with moderate-to-severe plaque psoriasis in Korea. Participants will be those who are candidates for phototherapy or systemic therapy and will begin treatment with deucravacitinib as per the approved product label. The study will collect real-world data to better understand the outcomes associated with this treatment in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult participants ≥19 years of age
* Diagnosis of moderate-to-severe plaque psoriasis
* Candidate for phototherapy or systemic therapy
* Will begin deucravacitinib according to approved product label

Exclusion Criteria:

* Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
* Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)

Where it's running

• Novotech Laboratory Korea Co., Ltd.
  Seoul, South Korea Recruiting
• Local Institution - 0001
  Seoul, South Korea Withdrawn

Study contacts

• Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HS-20137: a treatment option for adults with moderate-to-severe plaque psoriasis

  A phase 2 open-label study tests HS-20137 given as 200 mg at weeks 0, 4 and 8 to see if it is safe and helps patients with moderate-to-severe plaque psoriasis.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Beijing, Beijng · NCT07879885

• WD-890 in adults with moderate to severe plaque psoriasis

  This study tests whether WD-890 tablets work better than a placebo for adults with moderate to severe plaque psoriasis.

  Recruiting Phase 3 Zhejiang Wenda Pharma Technology LTD. · Nanjing, Jiangsu · NCT07672561

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

• Deucravacitinib added to current PsA treatment for difficult-to-control disease

  This study tests whether adding deucravacitinib to a patient’s existing Psoriatic Arthritis treatment can improve symptoms and quality of life for adults with hard-to-control disease.

  Recruiting Phase 4 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07280702

• TYK2 inhibitor for adults with moderate to severe plaque psoriasis

  This will test whether a TYK2 inhibitor taken for 12 weeks helps adults with moderate to severe plaque psoriasis improve their skin and symptoms.

  Recruiting Usynova Pharmaceuticals Ltd. · Shanghai · NCT07234591

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.